---

Query Drug：Futibatinib

Query Time：2024-08-21 14:24:12

*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

---

About the Drug

Futibatinib is used in adults to treat bile duct cancer that has spread (metastatic) or cannot be removed by surgery:

who have already received another treatment; and

whose tumor has an abnormal "FGFR2" gene.

Related Diseases

Extra Information on Drug and Diseases

Drug futibatinib

RXCUI: 2628190

May Treat

• Cholangiocarcinoma

Similar Drugs

[may_treat] Cholangiocarcinoma

Source MEDRT

• pemigatinib

• infigratinib

• futibatinib

[Physiological Effect] Cellular Communication Alteration

Source: MEDRT

• trilaciclib

• futibatinib

• omega-3 fatty acids

• fish oils

[Mechanism of Action] Kinase Inhibitors

Source MEDRT

• regorafenib

• idelalisib

• palbociclib

• osimertinib

• ribociclib

• neratinib

• duvelisib

• alpelisib

• pemigatinib

• capmatinib

• selpercatinib

• pralsetinib

• tepotinib

• umbralisib

• trilaciclib

• infigratinib

• mobocertinib

• pacritinib

• futibatinib

• leniolisib

• quizartinib

• clofarabine

• sorafenib

[Phamacological Category] Kinase Inhibitor

Source DAILYMED

• vandetanib

• vemurafenib

• crizotinib

• ruxolitinib

• axitinib

• bosutinib

• regorafenib

• cabozantinib

• ponatinib

• everolimus

• dabrafenib

• trametinib

• afatinib

• ibrutinib

• ceritinib

• idelalisib

• nintedanib

• palbociclib

• lenvatinib

• osimertinib

• cobimetinib

• alectinib

• ribociclib

• midostaurin

• brigatinib

• neratinib

• copanlisib

• abemaciclib

• acalabrutinib

• lorlatinib

• larotrectinib

• erdafitinib

• pexidartinib

• zanubrutinib

• avapritinib

• selumetinib

• pemigatinib

• tucatinib

• capmatinib

• ripretinib

• selpercatinib

• pralsetinib

• tepotinib

• trilaciclib

• tivozanib

• mobocertinib

• pacritinib

• futibatinib

• pirtobrutinib

• leniolisib

• quizartinib

• repotrectinib

• imatinib

• gefitinib

• erlotinib

• sirolimus

• sunitinib

• lapatinib

• sorafenib

• temsirolimus

• nilotinib

• pazopanib

[Phamacological Category] Kinase Inhibitor

Source FDASPL

• vandetanib

• vemurafenib

• crizotinib

• ruxolitinib

• axitinib

• bosutinib

• regorafenib

• cabozantinib

• ponatinib

• everolimus

• dabrafenib

• trametinib

• afatinib

• ibrutinib

• ceritinib

• idelalisib

• nintedanib

• palbociclib

• lenvatinib

• osimertinib

• cobimetinib

• alectinib

• ribociclib

• midostaurin

• brigatinib

• neratinib

• copanlisib

• abemaciclib

• acalabrutinib

• lorlatinib

• larotrectinib

• erdafitinib

• pexidartinib

• zanubrutinib

• avapritinib

• selumetinib

• pemigatinib

• tucatinib

• capmatinib

• ripretinib

• selpercatinib

• pralsetinib

• tepotinib

• trilaciclib

• tivozanib

• mobocertinib

• pacritinib

• futibatinib

• pirtobrutinib

• leniolisib

• quizartinib

• repotrectinib

• imatinib

• gefitinib

• erlotinib

• sirolimus

• sunitinib

• lapatinib

• sorafenib

• temsirolimus

• nilotinib

• pazopanib

[Physiological Effect] Cellular Proliferation Alteration

Source: MEDRT

• panthenol

• vandetanib

• vemurafenib

• crizotinib

• ruxolitinib

• axitinib

• bosutinib

• regorafenib

• cabozantinib

• ponatinib

• pomalidomide

• dabrafenib

• trametinib

• afatinib

• ibrutinib

• ceritinib

• idelalisib

• palbociclib

• osimertinib

• cobimetinib

• alectinib

• olaratumab

• ribociclib

• midostaurin

• brigatinib

• neratinib

• copanlisib

• abemaciclib

• acalabrutinib

• apalutamide

• encorafenib

• binimetinib

• lorlatinib

• larotrectinib

• gilteritinib

• glasdegib

• calaspargase pegol

• erdafitinib

• alpelisib

• polatuzumab vedotin

• darolutamide

• pexidartinib

• fedratinib

• entrectinib

• zanubrutinib

• avapritinib

• selumetinib

• pemigatinib

• sacituzumab

• tucatinib

• capmatinib

• ripretinib

• selpercatinib

• margetuximab

• eflapegrastim

• tremelimumab

• olutasidenib

• futibatinib

• elacestrant

• retifanlimab

• leniolisib

• quizartinib

• sotatercept

• tovorafenib

• imatinib

• lenalidomide

• etoposide

• dasatinib

• lapatinib

• sorafenib

• irinotecan

• temsirolimus

• nilotinib

[Mechanism of Action] P-Glycoprotein Inhibitors

Source DAILYMED

• vandetanib

• ticagrelor

• verapamil

• vemurafenib

• crizotinib

• ivacaftor

• mirabegron

• cobicistat

• lomitapide

• suvorexant

• eliglustat

• netupitant

• ledipasvir

• lumacaftor

• rolapitant

• flibanserin

• isavuconazole

• venetoclax

• velpatasvir

• voxilaprevir

• glecaprevir

• pibrentasvir

• neratinib

• lopinavir

• elagolix

• sarecycline

• clarithromycin

• erdafitinib

• avapritinib

• pemigatinib

• tucatinib

• capmatinib

• ripretinib

• selpercatinib

• berotralstat

• lonafarnib

• relugolix

• voclosporin

• tepotinib

• maribavir

• abrocitinib

• mitapivat

• pacritinib

• lenacapavir

• futibatinib

• elacestrant

• pirtobrutinib

• sparsentan

• sotagliflozin

• itraconazole

• cyclosporine

• ranolazine

• zonisamide

• etravirine

• ketoconazole

• nilotinib

• amiodarone

• sapropterin

• ritonavir

[Mechanism of Action] P-Glycoprotein Inhibitors

Source FDASPL

• vandetanib

• ticagrelor

• verapamil

• vemurafenib

• crizotinib

• ivacaftor

• mirabegron

• cobicistat

• lomitapide

• suvorexant

• eliglustat

• netupitant

• ledipasvir

• lumacaftor

• rolapitant

• flibanserin

• isavuconazole

• venetoclax

• velpatasvir

• voxilaprevir

• glecaprevir

• pibrentasvir

• neratinib

• lopinavir

• elagolix

• sarecycline

• clarithromycin

• erdafitinib

• avapritinib

• pemigatinib

• tucatinib

• capmatinib

• ripretinib

• selpercatinib

• berotralstat

• lonafarnib

• relugolix

• voclosporin

• tepotinib

• maribavir

• abrocitinib

• mitapivat

• pacritinib

• lenacapavir

• futibatinib

• elacestrant

• pirtobrutinib

• sparsentan

• sotagliflozin

• itraconazole

• cyclosporine

• ranolazine

• zonisamide

• etravirine

• ketoconazole

• nilotinib

• amiodarone

• sapropterin

• ritonavir

[Mechanism of Action] Breast Cancer Resistance Protein Inhibitors

Source DAILYMED

• cobicistat

• regorafenib

• dabrafenib

• tedizolid

• netupitant

• ledipasvir

• rolapitant

• osimertinib

• elbasvir

• velpatasvir

• safinamide

• voxilaprevir

• glecaprevir

• pibrentasvir

• tecovirimat

• lorlatinib

• avapritinib

• capmatinib

• ripretinib

• selpercatinib

• lonafarnib

• relugolix

• maribavir

• pacritinib

• oteseconazole

• lenacapavir

• futibatinib

• elacestrant

• pirtobrutinib

• sparsentan

• leniolisib

• itraconazole

• eltrombopag

• sapropterin

• ritonavir

[Mechanism of Action] Breast Cancer Resistance Protein Inhibitors

Source FDASPL

• cobicistat

• regorafenib

• dabrafenib

• tedizolid

• netupitant

• ledipasvir

• rolapitant

• osimertinib

• elbasvir

• velpatasvir

• safinamide

• voxilaprevir

• glecaprevir

• pibrentasvir

• tecovirimat

• lorlatinib

• avapritinib

• capmatinib

• ripretinib

• selpercatinib

• lonafarnib

• relugolix

• maribavir

• pacritinib

• oteseconazole

• lenacapavir

• futibatinib

• elacestrant

• pirtobrutinib

• sparsentan

• leniolisib

• itraconazole

• eltrombopag

• sapropterin

• ritonavir

[Mechanism of Action] Fibroblast Growth Factor Receptor Inhibitors

Source DAILYMED

• erdafitinib

• futibatinib

[Mechanism of Action] Fibroblast Growth Factor Receptor Inhibitors

Source FDASPL

• erdafitinib

• futibatinib

Orange Book

[Last update] 2024-08-09

Labelers

Futibatinib's Innovator is TAIHO ONCOLOGY INC

Drug Products

The unique dosage forms from the innovator include：1. TABLET;ORAL.

Index	Route	Brand Name	Labeler	Approval Date	Dosage
1	TABLET;ORAL	LYTGOBI	TAIHO ONCOLOGY INC	Sep 30, 2022	4MG

Drug Patents

This drug still has 3 effective patents.

Patent Number	Submission Date	Expiration Date	Drug Substance Patent?	Drug Product Patent?
9108973	Oct 24, 2022	Feb 23, 2033	Y	Y
10434103	Oct 24, 2022	Mar 31, 2036	Y	Y
11833151	Jan 3, 2024	Nov 5, 2039		Y

Related Company's Product Pipelines

The innovator TAIHO ONCOLOGY INC's portolio contains products with the following 2 API(s)： TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE, FUTIBATINIB

The above products are related to 4 diseases： Colorectal Neoplasms, Keratitis, Herpetic, Keratoconjunctivitis, Infectious, Cholangiocarcinoma